"The broken heart. You think you will die, but you just keep living, day after day after terrible day." -Charles Dickens' Great Expectations 1 There seem to be as many approaches to managing heart failure as there are causal factors. Heart failure management is evolving from a one-size-fits-all approach centered around therapy with neurohormonal antagonists toward strategies tailored to provide the optimal clinical benefit based upon individual patient profile. Thus, a major collective enterprise of the translational research community has been to identify subsets of patients that will derive greater benefit from one or another management scheme. The initial observation that, like cancer and other pathologies, microRNAs are regulated in heart disease 2 was coupled with observations that microRNAs are found circulating in stable form in the blood 3, 4 to raise expectations that microRNAs would prove useful as disease biomarkers, providing insights into aspects of heart disease not revealed through traditional clinical testing 5 . In the current issue of Circulation,
Melman et al propose miR-30d as a biomarker for heart failure responsiveness to cardiac resynchronization therapy 6 . This manuscript aptly illustrates the promise, problems, and pitfalls with the current state of evaluating microRNAs as biomarkers of cardiovascular disease. To quote Pip's sister in Great Expectations: "Answer him one question, and he'll ask you a dozen directly" 1 .
Melman et al 6 initially identified miR-30d as one of several microRNAs exhibiting statistically significant differences or a strong trend toward being differentially abundant in the plasma of patients who had undergone cardiac resynchronization therapy. The pilot microarray study of 12 male non-ischemic cardiomyopathy patients reflected the two extremes of response;
six non-responder subjects had no change or a decrease in left ventricular ejection fraction pathologies, microRNAs are regulated in heart disease 2 was coupled with observat at atio io ions ns ns t t tha ha hat t t microRNAs are found circulating in stable form in the blood 3, 4 to raise expectations that micr r roR oR oRNA NA NAs s s wo w w ul ul uld d d prove useful as disease bioma ma mark rk rkers, providing insigh gh hts ts t into aspects of heart d di dise e ease not reve e ea a ale ed d t t thr hr hrou ou ough gh gh t t tra ra radi di diti ti ion o o al a a cli i ini ni nica a al te est t ting g g 5 5 5 . In In In the h h c cur ur urre re rent nt nt i i iss sue o o of f f Ci Ci Circ rc rcul ul u at at atio io on n n, Me Me Melm lm lman et al al al pro o op po p se m m miR-3 3 30d d d as a a a bi iom om omar rke ke ker r r for r h h hea a art t fail il lur r re e e r re esp sp spon on o s s siv vene e ess s s to ca ca car r rdia ac e e esy s sync nc nchr hr hron on oniz i izat at atio io ion n n th th ther er erap ap apy 6 6 . T T Thi hi his s s ma ma manu n nusc sc scri ri ript pt pt a a apt pt ptly l ly i i ill ll llus s ustr tr trat at ates es es th th the e e pr pr prom om omis is ise e e, p p pro ro robl bl blem em ems s s, a a and nd nd p p pit it itfa fa fall ll lls s s (LVEF) and 6 responder subjects exhibited marked functional improvement (increase in LVEF averaging 24%). In an expanded cohort of 40 subjects, three of the microRNAs were confirmed as having significantly different circulating levels between categorical responders (here defined as an increase in LVEF of at least 10%) and categorical nonresponders (all others). The correlation data between log2 relative [miR-30d] and change in LVEF after synchronized biventricular pacing as depicted in Figure 2b of the manuscript, and are redrawn here and modified for purposes of illustration (Figure 1) . The correlation coefficient is reported as 0.39, p=0.01. These data reveal a 10 log2 range in relative miR-30d concentration. After censoring two outliers in which miR-30d levels are 2 and 4 logs greater than the highest values reported for the other 40 subjects (Figure 1 ) the authors indicate that the correlation between miR-30d plasma concentration and change in %LVEF after resynchronization no longer achieved significance. However, binary probabilistic modeling of categorical discrimination between responder and non-responder using circulating miR-30d levels as the variable (Figure 2c of Melman, et al 6 ) remained significant after removing the outliers.
What is currently known about miR-30d in the heart? Interrogation of extensive human and mouse heart miR-Seq data deposited in public databases reveals that miR-30d is one member of a family of identical or nearly-identical microRNAs (miR-30a, b, c, d, and e) that are abundant and present at remarkably similar levels in normal hearts of these two species 7, 8 , miR-30e, -30d, -30a, -30c, and -30b were ranked the 14 th Table 1 ). The latter study also assayed plasma samples and found that the most abundant miR-30 family member in plasma (assayed by small RNA sequencing) was miR-30d, which ranked as 12 th most abundant and was present at approximately 10% of the level of the most abundant circulating microRNA, miR-21 9 . Neither cardiac nor circulating blood microRNA sequencing data are available for experimental murine heart failure, but the entire miR-30 family is downregulated ~20% in the myocardium of mice early after experimental pressure overload induced by surgical transverse aortic coarctation 10 ( Table 1 , Supplemental Table 1 ). As confirmed by Melman and colleagues 6 , microRNA sequencing has
shown that miR-30d and the other miR-30 family members are more abundant in cardiac myocytes than in non-myocytes 7 .
Previous reports have suggested that plasma miR-30d levels are a biomarker for type 2 diabetes mellitus 11 , whereas whole blood levels of miR-30c are part of a panel of regulated circulating microRNAs associated with myocardial infarction 12 . miR-30d was recently observed to mediate programmed cardiomyocyte death in diabetic cardiomyopathy 13 , which contrasts with the anti-apoptotic actions reported by Melman, et al 6 .
It is not clear how increased circulating plasma miR-30d levels might identify heart failure patients more likely to respond to ventricular resynchronization. A recent microarray microRNA profiling study detected a decrease in circulating miR-30d in human heart failure 14 , which contrasts with the observation by Melman, et al that circulating plasma miR-30d levels are markedly higher in heart failure subjects than in non-failing volunteers 6 ; small RNA sequencing experimental pressure overload induced by surgical transverse aortic coarctation 10 0 ( ( (Ta Ta Tabl bl ble e e 1, 1, 1, Supplemental Table 1 ). As confirmed by Melman and colleagues 6 , microRNA sequencing has how w wn n n th th that at at m m miR-3 -3 -30d 0 0 and the other miR-30 famil l ly y y me m m mbers are more abu bu bund n n ant in cardiac m m myo oc o ytes than in in in n non on n-m -m -myo yo yocy cy cyte te tes s s 7 7 7 .
Prev v vio io ious re ep e or r rts s s hav ve e e su su sugg gg gges es este ed d t that t t pl pl plasma ma a m m miR iR iR-30d 0d 0d l lev ev evel l ls a a are e e a a bio io iom m marker er er for r ty y ype 2 2 di di diab ab abet et etes es es m m mel el elli li litu t tus s s 11 11 , wh h wher er erea ea eas s s wh h whol ol ole e e bl bl bloo oo ood d d le le leve e vels ls ls o o of f f mi mi miR R R-30 30 30c c c a a are re re p p par ar art t t of of of a a a p p pan an anel el el o o of f f re re regu g gula la late te ted d d of plasma from advanced human heart failure showed no significant change in circulating miR30d plasma small RNA sequence data from advanced human heart failure 9 . Thus, as has been recognized by virtually all investigators who are contributing to this nascent field, different microRNA assay methodologies and technical differences in sample handling or preparation complicate direct comparative analyses of these types of data.
Because all of the miR-30 family members are highly abundant in hearts, miR-30d may be passively released by injured or dying cardiomyocytes 15 . Importantly however, Melman et al detected an increase in vesicular miR-30d released from cultured neonatal rat cardiac myocytes subjected to repetitive mechanical deformation 6 , suggesting that miR-30d can be actively secreted. Nevertheless, stretching cultured neonatal cardiomyocytes is an imperfect model of ventricular dys-synchrony, and it is important to consider that increases in steady state plasma levels of a given microRNA may reflect greater miR secretion, enhanced miR biosynthesis, increased miR stability, or a combination of these mechanisms.
The promise of a new biomarker is that it will improve clinical discrimination for the condition that it marks, compared to the existing gold standard. The current gold standard for predicting a favorable response to ventricular resynchronization in heart failure is electrocardiographic QRS duration 16, 17 . As a categorical variable, QRS duration was part of the inclusion criteria for the study by Melman, et al 6 . However, likely because of limited cohort sizes, QRS duration did not predict resynchronization response. Thus, it is not possible to compare the new biomarker to the existing gold standard here because the gold standard failed.
It will be interesting to see if larger studies might in the future discover that the lack of exact predictive concordance between circulating miR-30d and QRS duration is advantageous, reflecting different aspects of heart failure that considered in combination comprise a superior The pr pr prom m mis s se o of f a a a new w w b b bio i i ma ma mark rker er er is th th tha a at it wi wi w ll i i im mp mpro ro ov ve ve cl l lin n nica ca cal d di iscri ri rim m minati i ion on on fo or the co co cond nd ndit it itio io ion n n th th that at at i i it t t ma ma mark rk rks s s, c c com om ompa pa pare re red d d to to to t t the he he e e exi i xist st stin in ing g g go go gold ld ld s s sta ta tand nd ndar ar ard d d. Th Th The e e cu c curr rr rren en ent t t go go gold ld ld s s sta ta tand nd ndar ar ard d d fo fo for r r response biomarker to either factor alone.
As noted by the authors, additional work is necessary before miR-30d can be accepted in either its proposed clinical role as a biomarker for predicting success of ventricular resynchronization therapy for heart failure, or mechanistically as a factor that is dynamically regulated in heart failure and favors cell growth over cell death. These uncertainties are certainly not unique to miR-30d, and seemingly reflect the current state of the field. Here, I will follow Mr. Jaggers' advice to Pip in Great Expectations "Take nothing on its looks; take everything on evidence" 1 and suggest ways in which research in this rapidly evolving area might evolve in order to fully meet our expectations:
When possible, initial biomarker discovery studies of circulating microRNAs should employ next generation sequencing. Hypothesis-generating research too often has to
compromise breadth of data coverage to assure accuracy of read-out, or vice versa. Fortunately, next generation sequencing is both the most comprehensive and most accurate method to profile RNA species of all sizes. Coverage is essentially complete; if a microRNA is present in even miniscule amounts it will be detected provided that sequencing depth is sufficient. miR-Seq provides better accuracy for microRNAs that undergo alternative processing (known as isomiRs)
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2.
Case-control associations should be validated in independent populations. The essence of experimental validation is independent replication. In the current era of comprehensive genomics it is standard practice for an initial report of a given genotypephenotype association to demonstrate independent replication of the index finding in one or more separate populations, as our group did some years ago with a common heart failure-associated polymorphism at 1p36.13 20, 21 . Of course, true validation requires that separate groups confirm the findings in even more independent cohorts, as was accomplished with 1p36.13 22, 23 . Adding additional subjects to an index cohort 6 , while helping to increase statistical confidence, is not sufficient for independent validation.
The predictive value of a biomarker, either for at-risk populations or individuals, must
ultimately be demonstrated prospectively. Even when a statistical association is demonstrated in multiple independent case-control populations, correlative data are not sufficient to demonstrate efficacy for a given metric to stratify individual risk or response. Indeed, there are many valid associations between levels of a marker and prevalence of a condition that, when applied to individuals, are poor clinical stratifiers or predictors because the correlation is not sufficiently tight, the variance is too great, or the marker is confounded by extraneous environmental or comorbid factors. It can be argued that including actual predictive data for individuals is too high a bar to set for initial biomarker discovery and characterization, in favor of binary probabilistic modeling 6 . Fortunately, it is not necessary to actually perform a prospective trial to assess thepredictive value of a novel biomarker. Existing outcomes data for the condition of interest he findings in even more independent cohorts, as was accomplished with 1p36. Drs. Melman, Das and colleagues are to be congratulated for attempting such a challenging project. A biomarker that improves the selection of heart failure cases for ventricular resynchronization has the potential to improve patient care, lower medical costs, and prevent ineffective device implantation in non-responders. Circulating microRNAs seem to be the "next big thing" in biomarkers, and for good reason. The current study adds to accumulating data supporting the concept that circulating microRNAs will become useful as biomarkers of heart disease, and extends this notion to a biomarker predicting the specific therapeutic response to a form of targeted disease management. Circulating microRNAs would be readily obtainable from patients via simple venipuncture, and a limited panel of dozens or hundreds of validated microRNA biomarkers could be assayed in whole blood, serum, or plasma using standardized arrays; such data would be comparable across different centers. Because release or secretion of microRNAs is likely modulated by features of cardiovascular diseases that differ from those that promote the release of circulating protein biomarkers assayed by standard clinical tests, one of the expectations is that circulating microRNA biomarkers will add to our understanding of disease pathogenesis as well as refine clinical decision making. For this purpose, whether a circulating microRNA is actively or passively released and the extent to which it induces a biological effect (as via cell-to-cell communication) does not impact its utility as a biomarker.
Both issues are interesting and important, but are capable of being addressed independently.
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